Immuneering Corp
Clinical-stage oncology company developing medicines using computational technology.
IMRX | US
Overview
Corporate Details
- ISIN(s):
- US45254E1073
- LEI:
- Country:
- United States of America
- Address:
- 245 MAIN STREET, SECOND FLOOR, 2142 CAMBRIDGE
- Website:
- https://immuneering.com/
Description
Immuneering Corp. is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. The company utilizes its proprietary computational Disease Cancelling Technology to design and develop novel therapeutics. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of the MEK pathway. Atebimetinib is being evaluated in Phase 2a clinical trials for patients with advanced solid tumors, including pancreatic cancer. The drug is designed to maximize therapeutic activity while providing an improved tolerability profile, with the goal of helping patients outlive their disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immuneering Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immuneering Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immuneering Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
